

NEWS RELEASE

FOR IMMEDIATE RELEASE

February 4, 2019

Methapharm announces R&D investment

Methapharm is pleased to announce that it has entered into an agreement with the Biointerfaces Institute of McMaster University for the development of a novel diagnostic product platform.

About Methapharm

Methapharm is a privately held specialty pharmaceutical company that focuses on the development, acquisition, licensing, and promotion of healthcare products in North America. Methapharm markets its own proprietary products, and partners with global companies to promote products in the USA and Canada. This investment accords with Methapharm's strategy to acquire marketed products as well as invest in promising early-stage opportunities.

About the Biointerfaces Institute

The McMaster Biointerfaces Institute has the ability to rationally and rapidly develop new biomaterials with surfaces engineered to have the appropriate interactions with the intended biological environment. Using the latest technologies in high-throughput synthesis and screening to prepare and screen biointerfaces and biomaterials, the 10,000 square foot facility has state-of-the-art equipment and dedicated, professional research scientists.

###

For more information about Methapharm or business development inquiries, please contact:

Craig Baxter
President
Tel: (+1) 519.751.3602 x7230

Chris Calenti
Exec. Vice President (BD & Licensing)
(+1) 519.751.3602 x7222